U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908953) titled 'Prospective Evaluation of Recombinant Pbserum Plus(R) and Pbserum HA 2.0(R) in Aesthetic and Regenerative Bioremodeling' on Aug. 31.
Brief Summary: This study will evaluate the efficacy and safety of recombinant enzymes contained in pbserum Plus(R) and pbserum HA 2.0(R) for aesthetic and regenerative tissue bioremodeling.
The study will include adult participants with clinical conditions such as facial or body skin laxity, localized adiposity, cellulite, tissue fibrosis, subcutaneous nodules, and pathological scars. Participants will be evaluated according to the specific clinical condition being treated.
The study will assess chan...